How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world

Andrea Pretta, Dario Spanu, Stefano Mariani, Nicole Liscia, Pina Ziranu, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Mario Scartozzi, Eleonora Lai

Specialty type: Oncology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Valente R, Sweden; Yang ZG, China
Received: January 5, 2022
Peer-review started: January 5, 2022
First decision: February 15, 2022
Revised: April 1, 2022
Accepted: May 5, 2022
Article in press: May 5, 2022
Published online: May 24, 2022

Abstract
As underlined in the minireview by Blomstrand et al, given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma (PDAC), additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed. The real-world outcomes of first-line chemotherapy regimens such as FOLFIRINOX and gemcitabine/nab-paclitaxel are thoroughly reviewed and seem to be largely generalizable in a real-world context. Regarding second-line chemotherapy, the key question about the optimal sequence of regimens remains uncertain. Precisely in this setting, it is therefore useful to encourage the implementation of clinical studies that may contribute to the scarcity of data available up to now. We report our experience with a small group of patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. To improve the treatment of patients affected by PDAC, it is useful to identify subgroups of patients who may benefit from target treatments (e.g., BRCA mutant) and it is also important to focus on any prognostic factors that may affect the survival and treatment of these patients.

Key Words: Metastatic pancreatic ductal adenocarcinoma; Palliative chemotherapy; Real-world data; Molecular selection; Biomarkers; Second-line treatment

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
**Core Tip:** The present letter is intended to contribute to the collection of data on pancreatic ductal adenocarcinoma (PDAC) treatments in second-line settings through our experience with the promising data of efficacy and safety of a small group of study patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. We also focused on highlighting the subgroups of PDAC patients who might benefit from target treatments, such as a small proportion of mutated BRCAxs, and to identify comorbidities or characteristics that impact the prognosis of PDAC patients through our retrospective analysis that demonstrate a correlation between type II diabetes mellitus and improved overall survival.

**Citation:** Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzeno M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world. *World J Clin Oncol* 2022; 13(5): 417-422

**URL:** https://www.wjgnet.com/2218-4333/full/v13/i5/417.htm

**DOI:** https://dx.doi.org/10.5306/wjco.v13.i5.417

---

**TO THE EDITOR**

We read with great interest the review by Pretta et al[1], entitled “Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer”. This review provides a comprehensive overview on real-life data of metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated in the first- and second-line setting. The authors critically compare the results obtained in a real-world population with those provided by randomised clinical trials (RCT), highlighting that the outcomes are consistent and similar, especially on first-line with FOLFIRINOX and gemcitabine-nab-paclitaxel.

We agree with the authors that PDAC patients enrolled in RCT represent a highly selected population and that despite real-world outcomes derive from different countries, with various regulatory agencies and health care systems, all data available in the literature seems to confirm the effectiveness and safety of chemotherapy regimens in real-life settings. Moreover, since no strong data on second-line settings are available, we greatly appreciate the authors’ effort to analyse this topic.

At our Centre, we conducted a retrospective analysis in a real-world population of metastatic PDAC patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5FU/LV) in a compassionate use program, in order to assess clinical outcome, tolerability and potential prognostic factors. Statistical analysis was performed with the MedCalc package. The association between categorical variables was estimated by chi-square test. Survival distribution was estimated by the Kaplan-Meier method and survival curves comparison was evaluated with the log-rank test. The cut off value for laboratory parameters was identified with ROC curves. The study was approved by the Ethical Committee of the Cagliari University Hospital (Prot. PG /2018/7339, June 1, 2018) and was performed in accordance with the ethical principles stated in the Declaration of Helsinki and in the International Conference on Harmonization (ICH) Note for Guidance on Good Clinical Practice (GCP, ICH E6, 1995) and all applicable regulatory requirements.

Globally, 14 patients treated with nal-IRI and 5FU/LV from June 2016 to November 2018 were included in our analysis. Baseline characteristics are shown in Table 1. Median overall survival (OS) was 9.1 (95%CI: 5.8-13.1) mo. Median progression free survival (PFS) was 7.2 mo (95%CI: 3.0-33.8). Three patients achieved a partial response, two had stable disease, and nine developed progression. Median duration of treatment with nal-IRI plus 5FU/LV was 6 mo; treatment longer than 6 mo was related to improved OS [13.1 mo (95%CI: 9-17) vs 7.1 mo (95%CI: 2.9-13.1), P = 0.0127, HR = 0.18] and PFS [9.1 mo (95%CI: 7.2-33.8) vs 3.1 mo (95%CI: 2.2-7.7), P = 0.0011, HR = 0.08]. Baseline haemoglobin levels equal or lower than 10 g/dL were associated with worse prognosis [OS: 11 mo (95%CI: 1-15.9) vs 3 mo, P = 0.0384, HR = 0.005; PFS: 7.6 mo (95%CI: 3.1-33.8) vs 3 mo, P = 0.0384, HR = 0.005]. 64% of patients developed grade > 2 toxicity. The occurrence of grade > 2 anaemia was related to shorter OS [3 mo vs 11 mo (95%CI: 7.1-15.9), P = 0.0384, HR = 0.005] and PFS [3 mo vs 7.6 mo (95%CI: 3.1-33.8), P = 0.0384, HR = 0.005]. As shown in the Kaplan-Meier method and survival curves comparison was evaluated with the log-rank test. The cut off value for laboratory parameters was identified with ROC curves. The study was approved by the Ethical Committee of the Cagliari University Hospital (Prot. PG /2018/7339, June 1, 2018) and was performed in accordance with the ethical principles stated in the Declaration of Helsinki and in the International Conference on Harmonization (ICH) Note for Guidance on Good Clinical Practice (GCP, ICH E6, 1995) and all applicable regulatory requirements.

As underlined by Blomstrand et al[1], there is an urgent need for prognostic and predictive biomarkers to improve the therapeutic management of PDAC patients and to prolong survival as well as more effective treatment strategies. Indeed, intensive research efforts and substantial progress in the
understanding of the PDAC genetic background and molecular biology have not yet been matched either by the successful development of novel agents or by the identification of predictive biomarkers that could increase the effectiveness of existing therapies[5]. In contrast to other solid tumours, immunotherapy strategies have failed to yield any notable impact in PDAC. This is likely related to the critical role of the tumour microenvironment as a physical barrier and its inhibitory immune signalling. The most promising therapeutic strategy seems to be combination of immunotherapeutics with other targeted treatments[6].

To our knowledge, the only successful biomarker-driven phase III RCT so far is the POLO trial, which showed improved PFS with maintenance Olaparib, a PARP-inhibitor, vs placebo in germline BRCA-mutant PDAC not progressing after first-line platinum-based chemotherapy[7]. Notably, BRCA-mutant PDAC represents a unique entity with specific disease features that are still to be fully understood and BRCA1/2 alterations are the most explored targetable mutations. Moreover, in this patients’ setting, the sensitivity to platinum chemotherapy requires further research and confirmations. Recently, the concept of “BRCAness” has gained increasing importance. This term refers to high-grade genomic instability of non-BRCA-mutant cancers and represents a phenotype of defective homologous recombination to which somatic mutations in genes like BRCA1/2, ATM, PALB2, CHEK1, RAD51, and FANCA, can contribute. For these reasons, “BRCAness” is under evaluation as a biomarker for DNA-damaging agents and PARP inhibitors[8].

Finally, we believe that in a real-life focusing-approach, a particular focus should be deserved to the assessment of the impact of comorbidities on the PDAC patients’ prognosis. In a retrospective analysis that we conducted on 164 advanced PDAC patients, we demonstrated a correlation between type II diabetes mellitus and improved OS, both in the exploratory and in the validation cohort at univariate analysis (16 vs 10 mo; \( P = 0.004 \) and 11 vs 6 mo; \( P = 0.01 \), respectively). Moreover, in multivariate

| Baseline characteristics                  | Patients, % |
|------------------------------------------|-------------|
| Sex                                      |             |
| Male                                     | 71          |
| Female                                   | 29          |
| Age, yr                                  |             |
| < 65                                     | 36          |
| ≥ 65                                     | 64          |
| Location of primary tumour               |             |
| Head-uncinate process                    | 57          |
| Body                                     | 21.5        |
| Tail                                     | 21.5        |
| Previous surgery                         |             |
| Yes                                      | 28.5        |
| No                                       | 71.5        |
| Number of metastatic sites               |             |
| Single site                              | 36          |
| Multiple sites                           | 64          |
| Location of metastatic sites             |             |
| Lymph nodes                              | 78.5        |
| Liver                                    | 57          |
| Peritoneum                               | 42.8        |
| Lung                                     | 35.7        |
| First-line chemotherapy regimen          |             |
| Gemcitabine-nab-paclitaxel               | 92.8        |
| Other                                    | 7.2         |
Figure 1 Kaplan-Meier overall survival and progression free survival curves according to clinical variables. A: Overall survival (OS) Kaplan-Meier curve according to nal-IRI treatment duration; B: Progression free survival (PFS) Kaplan-Meier curve according to nal-IRI treatment duration; C: OS Kaplan-Meier curve according to baseline haemoglobin levels; D: PFS Kaplan-Meier curve according to baseline haemoglobin levels; E: OS Kaplan-Meier curve according to occurrence of grade > 2 anaemia; F: OS Kaplan-Meier curve according to occurrence of grade > 2 anaemia; G: OS Kaplan-Meier curve according to the need for
erythropoietin administration; H: PFS Kaplan-Meier curve according to the need for erythropoietin administration.

In conclusion, in the era of precision medicine, larger and prospective studies in the real-world population, with the focus on specific PDAC subtypes (e.g., BRCA-mutant), would further clarify the impact of available and innovative treatment strategies on PDAC patients and help identify potential biomarkers to improve patients’ selection and prognosis.

ACKNOWLEDGEMENTS
We acknowledge all the authors whose publications are referred in our article.

FOOTNOTES
Author contributions: All authors wrote and edited the manuscript.

Conflict-of-interest statement: Prof. Scartozzi reports associations with Amgen, Sanofi, MERCK SHARP DOHME, Eisai, Merck, and Bayer, outside the submitted work.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Italy

ORCID number: Andrea Pretta; Mario Scartozzi

REFERENCES
1 Blomstrand H, Batra A, Cheung WY, Flander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol 2021; 12: 787-799 [PMID: 34631442 DOI: 10.5306/wjco.v12.i9.787]
2 Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019; 108: 78-87 [PMID: 36654298 DOI: 10.1016/j.ejca.2018.12.007]
3 Wang-Gillam A, Li CP, Bodoky G, Dean A, Sloan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blane JF, Hubner RA, Chiu CF, Schwartsman G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhinda N, Bayvor E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545-557 [PMID: 26615328 DOI: 10.1016/S0140-6736(15)00986-1]
4 Pellino A, Manai C, Mez V, Scarzotti M, Milella M, De Vita F, Antonuzzo L, Zichi C, Satolli MA, Noventa S, Giordano G, Nappo F, Zecchetto C, Puzzoni M, Vaccaro V, Pappalardo A, Giommoni E, Melisi D, Lonardi S. Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis. J Clin Oncol 2020; 38: 660-660 [DOI: 10.1200/JCO.2020.38.4_suppl.660]
5 Lai E, Pretta A, Lai E, Persano M, Donisi C, Pinna G, Sinibaldi E, Pretta A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Puzzoni M, Visani P, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets 2021; 25: 987-1005 [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044]
6 Pretta A, Lai E, Persano M, Donisi C, Pinna G, Sinibaldi E, Pretta A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Puzzoni M, Visani P, Scartozzi M. Improving pancreatic cancer patients' selection and prognosis. Expert Opin Ther Targets 2021; 25: 987-1005 [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044]
Pretta A et al. Improving pancreatic cancer patients’ selection

7 Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019; 381: 317-327 [PMID: 31157963 DOI: 10.1056/NEJMoa1903387]

8 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puozzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. *Br J Cancer* 2021; 125: 1321–1332 [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9]

9 Pretta A, Ziranu P, Puozzoni M, Lai E, Orsi G, Liscia N, Molinaro E, Mariani S, Riggi L, Rovesti G, Dubois M, Migliari M, Persano M, Saba G, Impera V, Musio F, Batzella E, Demurtas L, Pusceddu V, Astara G, Faloppi L, Casadei Gardini A, Andrikou K, Cascinu S, Scartozzi M. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. *Tumori* 2021; 107: 550-555 [PMID: 33243068 DOI: 10.1177/0300891620976945]
